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Gabapentins (GBP) is structurally similar to GABA yet its mode of action remains uncertain. It is water-soluble and GI tract
absorption occurs via the l-amino acid transport system in the proximal small bowel. It has been suggested that this transportation
is capacity limited, thus decreasing GBP bioavailability at higher doses. GBP is not protein bound, therefore, salivary levels
might be expected to be similar to those in serum; also the drug does not induce hepatic enzymes and is excreted unmetabolised
by the kidney. Within the dose-range normally prescribed, it is devoid of pharmacokinetic (PK) drug interactions with all other
anti-epileptic drugs.
This study assesses two things in patients with epilepsy: (a) bioavailability of higher doses of GBP (1200–4800 mg per day), and
(b) the influence of high dose GBP on between-dose serum concentrations of co-prescribed anti-epileptic drugs. After stabilising
at each dosage, a sequence of serum and saliva samples were collected within the dosage interval; GBP and co-medication
concentrations were determined and the results subjected to PK modelling.
Meaned results from 10 patients indicate that GBP continues to be absorbed in a reasonably linear manner relative to dose up
to 4800 mg per day. The study also shows that GBP is transported into saliva, however, salivary concentrations are only 5–10%
of those in plasma. Furthermore, the results indicate that GBP, in higher than recommended doses, did not change plasma
concentrations of lamotrigine, carbamazepine, carbamazepine-epoxide, vigabatrin, primidone, phenobarbitone or phenytoin
when added to treatment.
It is concluded that larger than recommended doses of GBP can be efficiently absorbed by some patients and also that GBP
plasma levels do not fluctuate greatly between dosage intervals, therefore, twice daily dosage is a possibility.
© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
Gabapentin (GBP) is a relatively new anti-epileptic
drug that is structurally similar to GABA and is appro-
ved as add-on therapy for treatment of partial seizures
with or without secondary generalisation. Its mode
of action remains unclear1, 2. Following initiation of
treatment the dose can be escalated quite rapidly with
a recommended maximum in adults of 2400 mg per
day. The drug is absorbed from the proximal small
bowel into the blood stream by the l-amino acid trans-
port system and bioavailability of GBP is reported to
be dose-dependent, possibly because the l-amino acid
transport system is capacity limited3, 4. Peak serum
levels of GBP occur 1–2 hours post-ingestion and the
drug is subsequently eliminated via the kidneys with-
out metabolism. It is not protein bound. Plasma GBP
concentrations are reported to increase linearly with
dose up to about 1.8 g per day. Plasma levels continue
to increase at higher doses, but less than expected. The
non-linear relationship between dose and plasma level
is thought to arise from saturable absorption of GBP
from the intestine5, and it is proposed that a maximum
dose of about 5 g per day could be absorbed.
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More recently, pre-morning dose serum GBP con-
centrations in 228 patients with epilepsy were studied6
which showed that individual patients produced a
significant correlation between serum level and dose
within the daily range of 400–4800 mg. Up to 6 g per
day GBP were administered to patients in another
recent study7 and blood was collected for drug deter-
mination which showed that serum levels increased at
each dose increment, but there was decreased bioavail-
ability at the high doses. Plasma GBP concentrations
ranged from 5.9 to 21.9 mg/l (34.5–127.9µmol/l).
It was concluded that high doses of GBP can be
absorbed and may be effective in a proportion of
patients.
The present study investigates GBP disposition in
epileptic patients undergoing escalation to higher
doses than currently recommended. It is the first study
to provide dose-to-dose pharmacokinetic (PK) eval-
uation to examine the absorption of GBP following
high dose escalation.
For many of the anti-epileptic drugs, salivary con-
centrations reflect the free (non-protein bound) frac-
tion in plasma and may, therefore, correlate better
than total plasma levels with the clinical effects8.
Furthermore, a strong correlation between saliva and
plasma drug levels enables one to consider saliva as
an alternative biofluid for therapeutic drug monitor-
ing (TDM) in patients who are averse to venesection.
Since GBP is not protein bound9, 10 it might be ex-
pected that salivary levels would be similar to those
in serum or plasma. A second objective of this study
was to investigate whether GBP is transported into
saliva and, if so, to see if a useful relationship exists
between plasma and salivary GBP concentrations.
GBP is reported not to interact pharmacokinetically
nor to alter serum levels of any other anti-epileptic
drugs, but high doses of GBP have not investigated. A
further aim of this study was to evaluate the possible
effect of such high doses of GBP on between-dose
areas under the plasma concentration/time curve




This study was an additional component to the AUS-
STEPS trial11 as approved by the Human Research
Ethics Committee of Royal North Shore Hospital,
Sydney. The addition of an extra dosage escalation
up to 4800 mg per day was appended to the protocol
as an amendment after initiation of the AUS-STEPS
trial that provided for an 8-week baseline period
during which medication remained unchanged and
clinical assessments of seizure control and adverse
events were undertaken. Each subject then received
maintenance doses of GBP, which were escalated
at monthly intervals from 1200 to 4800 mg per
day (taken as three divided doses) depending upon
clinical response and patient preference. Follow-
ing stabilisation at each new dosage, a sequence of
timed blood and matching saliva samples were col-
lected for determination GBP of and co-medication
concentrations.
Subjects
Ten subjects who were eligible for inclusion into the
AUS-STEPS trial were invited to participate in the
additional protocol at the time of recruitment. They
were prescribed not more than two anti-epileptic med-
ications at study entry and co-medication remained
unchanged throughout.
Protocol
At each baseline study visit, a 10 ml (clotted) blood
sample was collected to determine the concentrations
of current medication. After completing the 8-week
baseline period, further blood was collected before
initiating GBP treatment with rapid escalation over 3
days to a dosage of 1200 mg per day (400×3) by Day
4. After 4 weeks treatment, the patients returned for
clinical assessment and collection of blood and saliva
for the PK profile. Blood collection was carried out as
follows.
Following an overnight fast, 5 ml blood was with-
drawn and allowed to clot after which the current
morning dose of GBP was administered (for first test
400 mg) and 5 ml blood was then collected pre-dose
and at 1–6 hours post-dose. Each sample was cen-
trifuged immediately after collection and the serum
transferred to another tube.
About 1–3 ml of saliva was also collected at the
same time by giving the patient a ball of inert thermo-
plastic to chew, thereby stimulating salivary flow and
collecting the saliva in a 5 ml serum tube. All samples
were frozen at −20 ◦C to await drug analysis.
The GBP dose could then be escalated to the next
level (1800 mg per day as 600 × 3) depending upon
changes in seizure control or the appearance of ad-
verse events. After 4 weeks at the revised dose, the
PK profile was repeated as described before, by first
collecting a pre-dose blood and saliva followed by
hourly sampling after ingesting 600 mg GBP. Depend-
ing upon their response to the previous treatment pa-
tients could be dose escalated to 2400 mg per day
(800× 3). After 4 weeks stabilisation, the PK profile
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was repeated as before with the morning dose being
800 mg GBP following which the dose was escalated
to 3600 mg per day (1200 × 3) depending upon the
previous response. After 4 weeks stabilisation at the
revised dose, the PK profile was again repeated taking
care to collect a pre-morning dose sample and the same
sequence followed after a morning dose of 1200 mg.
Patients could then be dose escalated to 4800 mg per
day (1600×3) depending upon their clinical response.
After 4 weeks stabilisation at the highest dose, a PK
profile was repeated by collecting pre-morning dose
samples and continuing the sequence as before after a
morning dose of 1600 mg.
Drug measurement
GBP was determined by modifying the reversed phase
high performance liquid chromatographic (HPLC)
method of Hengy and Kolle12. The procedure in-
volved adding an internal standard (PD 403609 in
acetone) to a small serum or saliva sample, allowing
the proteins to precipitate and centrifuging before
evaporating the supernatant liquid to dryness. The
residue was then derivatised with picrylsulphonic
acid following which the reaction was stopped before
extracting with hexane. The derivatives were sub-
sequently separated by reversed phase HPLC with
detection at 340 nm. Quantification was by reference
to calibration standards made by spiking GBP into
serum or saliva over the appropriate concentration
range. These were carried through the procedure with
each lot of analysis and every analytical batch was
subjected to quality control at two concentrations.
Concurrent anti-epileptic medication concentrations
were determined in the plasma samples by fully vali-
dated HPLC and gas chromatographic techniques.
When appropriate the concentrations of pharmaco-
logically active metabolites were also determined.
Data analysis
Serum GBP concentration versus time after dose was
plotted at each dose in each individual, and the 6 hours
AUC was calculated by applying the trapezoidal rule.
In addition, the means of all data were calculated in
order to arrive at an average result.
The effect of dose on AUC was analysed using a
randomised block design. Each of the 10 subjects was
considered as a block to account for subject-to-subject
variability. The five doses (1200, 1800, 2400, 3600 and
4800) were considered to be the treatment effects. As
there was missing data the regression approach to the
analysis of the randomised block design was taken13.
The linearity relationship between the AUC and dose
was investigated using linear regression analysis with
the test for lack of fit. MINITAB 11 was used for all
the statistical analysis.
Salivary GBP concentration versus time after dose
was plotted at each steady state dose in each individual
and the 6 hours (AUC) was calculated by applying the
trapezoidal rule. All data were subsequently meaned
in order to arrive at an average result.
Co-medication drug and metabolite concentration
versus time after dose was plotted for every dose in
each individual, and the 5/6 hours AUC was calculated
for each compound by applying the trapezoidal rule.
When several patients were prescribed the same drugs
the data were meaned in order to arrive at an average
result.
RESULTS
Fig. 1 shows the meaned time versus serum GBP pro-
files for the pooled data from all patients at each dose.
Four patients completed the 4800 mg dose schedule
whilst six completed the 3600 and 2400 mg and eight
completed the 1800 mg.
Data analysis revealed a significant variability from
subject to subject (P < 0.05) and also that AUC was
dependent on the dose (P < 0.001). Linear regression
of the AUC versus dose data was fitted by a straight
line. The repeated values at different doses enabled
the study of linear trend, i.e. testing the lack of fit of a
linear function. It was found that the linear regression
was significant (P < 0.05). There was no lack of
fit (P = 0.6495) which implied the existence of a
linear trend, i.e. within the dose-range studied, AUC
increased as dose increased.
GBP has a serum elimination t1/2 of 5–9 hours and
Fig. 1 also shows that at steady state the plasma
GBP concentrations fluctuate less than expected be-
tween dose intervals. Time to peak concentration
is 2–3 hours and with the 4800 mg per day treat-
ment the mean, between-dose GBP plasma level was
13.6 mg/l (79.4µmol/l) with a SD of only 2.4 mg/l
(14.0µmol/l). The effect is similar to sustained re-
lease and probably arises because absorption takes
place from the small bowel and is regulated by an
active transport mechanism.
Fig. 2 is a plot of meaned AUC at each dosage
versus dose and this indicates an essentially linear
relationship between AUC and dose throughout the
range investigated. The equation of the line is: AUC =
7.64+0.0125×Dose, however, there were substantial
inter-individual differences in the dose to serum level
relationship which may reflect individual differences
in l-amino acid transport capacity.
Fig. 3 shows meaned time versus salivary GBP pro-
files of the pooled data for all patients at each dose.
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Fig. 1: Meaned time versus serum GBP profiles for the data pooled for all volunteers at each dose (1 mg/l = 5.84µmol/l). Four
volunteers completed the 4800 mg dose whereas six completed 3600 and 2400 mg while eight completed 1800 mg.
Comparing this with the corresponding serum levels
enables one to see that the salivary GBP concentra-
tions were only 5–10% of those in serum, but there
was substantial inter- and intra-subject variability. Ap-
proximately 10% of the saliva samples were either
Fig. 2: A plot of meaned AUC±SD for all patients at each dosage versus GBP dose (mg per day). The line of best fit is inserted.
not collected or leaked in transit causing a substantial
amount of data to be missing.
Fig. 4 is a plot of meaned salivary AUC at each
dosage which indicates a reasonably linear rela-
tionship throughout the dose-range investigated, the
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Fig. 3: Meaned time versus salivary gabapentin concentration profiles for the pooled data from all volunteers at each dose.
equation of the line being: AUC = 0.5095+0.0015×
Dose.
Co-medication AUC data could be evaluated in only
8 of the 10 patients that entered the study since two did
not escalate above the lowest GPT dose. Between-dose
interval co-medication PK studies were performed in
those patients who were stabilised on a range of GBP
doses while their co-medication remained unchanged.
Six patients had PK performed at 1200, 1800, 2400
Fig. 4: Meaned salivary GBP AUC± SEM for all patients at each dosage versus GBP dose (mg per day).
and 3600 mg per day of GBP and, of these, four also
had PK determined at 4800 mg per day GPT. The re-
maining two patients only escalated GBP to 1800 mg
per day. Co-medication prescribed is summarised in
Table 1.
Fig. 5 summarises the mean co-medication AUCs at
each GBP dose for all patients prescribed phenytoin,
carbamazepine, lamotrigine and vigabatrin. For those
patients on carbamazepine the epoxide AUCs were
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Table 1:






Fig. 5: Mean± SEM AUC of the various co-medicaments at increasing GBP doses. Key: PYTO, phenytoin; CARB,
carbamazepine; EPOX, carbamazepine-epoxide; VIGA, vigabatrin; LAMO, lamotrigine; POBA, phenobarbitone; PRIM,
primidone.
Fig. 6: AUC of primidone and metabolite at increasing GBP doses—patient VTC.
calculated and are shown also. It is evident that the
AUC for all these drugs remains constant as GBP
doses are increased. One patient (VTC) was prescribed
primidone and the AUC for both parent drug together
with the metabolite, phenobarbitone, are illustrated
(see Fig. 6). These also remained constant through-
out the study. The only patient whose serum drug
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Fig. 7: AUC of phenytoin at increasing pentin doses—patient can.
concentrations changed significantly was CAN
(Fig. 7). This patient was prescribed phenytoin alone,
however, the serum levels did not change in the other
two patients on phenytoin.
DISCUSSION
These data for meaned plasma GBP concentrations,
showed a proportional increase in the serum levels
with higher doses and a linear increase in AUC with
doses up to 4800 mg per day. Furthermore, the vari-
ation in serum concentration between dose intervals
was less than expected for a drug with an elimina-
tion half-life of only 5–9 hours which indicates that
the recommended three or four times daily dosing is
probably unnecessary.
These results bring into question the concept of a
saturable absorption and, hence limited bioavailability
of GBP at least up to a dosage level of 4800 mg since
there was a linear increase of absorption at the higher
dosage in our patients. These findings support those of
May et al.6 and Wilson et al.7 and disagree with those
of Richens14, who reported that while bioavailability
of single doses ranged from 42 to 57%; this dropped to
35% on a multi-dose regimen of 1600 mg given three
times a day.
A possible explanation could relate either to the
study population being refractory patients with
epilepsy on polypharmacy which might enhance ab-
sorption of GBP or there could be an altered l-amino
acid transport consequent to epilepsy as compared
with that found in the healthy subjects used for phase
one PK studies4. Alternatively, the proportionally
increased absorption might reflect the recruitment
of an another absorption mechanism, e.g. passive
diffusion.
These findings refute the concept of saturability of
absorption, at least to a dosage of 4800 mg and indi-
cate that bioavailability continues to be maintained.
Thus, in the absence of clinical efficacy, increas-
ing the dose of GBP in excess of the maximum
recommended would be justified. The results bring
into question the basis of the recommended upper
dose limit of 2400 mg as defined both in the United
Kingdom and Australia, and highlights the need to
review PKs on an inter-dose approach of some of the
new anti-epileptic medications in patients rather than
healthy volunteers.
A further aim of this study was to determine
whether GBP was transported into saliva in sufficient
quantity to allow salivary GBP levels to be measured
as an alternative to serum. The results indicate that
saliva could provide an alternative vehicle for the
determination of GBP levels, however, since sali-
vary concentrations are much lower than those in
serum it is important to validate the analytical method
over the range of values expected and in the same
matrix.
GBP is not protein bound9, 10, so one might rea-
sonably expect salivary levels to directly mirror those
in serum, however, salivary GBP concentrations in
this study were only 5–10% of those in serum. Lit-
tle has been published regarding GBP secretion into
saliva, although Taylor15 stated that the very high
hydrophilicity of GBP, with an octanol:water parti-
tion coefficient of approximately 0.05, may limit its
passage across biological membranes. The present
findings agree with the limited information that is
available16 (Bockbrader, personal communication).
Anti-convulsant drug concentrations in CSF are
often the same as the unbound fraction in plasma.
Earlier studies with GBP in rats have demonstrated
that CSF concentrations are also only 5–10% of the
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unbound serum fraction16 and this may also be
related to its hydrophilic character15.
The present study has shown a linear relationship
between increasing salivary GBP concentrations and
dose up to 4800 mg per day (Fig. 4), however, absorp-
tion of GBP into saliva is limited as has been found
with CSF17.
While salivary levels are much lower than those in
serum they do provide a means of assessing GBP lev-
els in serum. A limiting factor was the considerable
dose-to-dose fluctuation of salivary GBP levels in any
individual patient. This suggests that the only prag-
matic role for salivary level GBP assessment would
be to confirm that the patient has taken GBP rather
than to meet the more demanding rigor of therapeutic
monitoring in clinical practice.
Regarding the third aim of the study, to assess
the effects of higher than normal doses of GBP on
co-medication serum levels in a routine clinical care
situation, the number of subjects is small, but the
detailed assessment of between-dose PK is the most
rigorous, thus far undertaken. It has examined PK
of concomitant anti-epileptic drugs in patients who
were exposed to up to double the recommended GBP
dosage. The mean serum AUC graph (Fig. 5) indi-
cates that co-medication bioavailability remains con-
stant with increasing dosages of GBP for phenytoin,
carbamazepine, lamotrigine and vigabatrin. Further-
more, the bioavailability of carbamazepine-epoxide,
the pharmacologically active metabolite of carba-
mazepine, did not change. While these findings are
those expected from published data on the disposi-
tion/PK of GBP9 we have shown that increasing GBP
doses and serum levels up to double the recommended
maximum does not alter either the absorption or elim-
ination of a range of common anti-epileptic drugs.
The one confounding patient was CAN (Fig. 7) in
whom phenytoin levels fluctuated considerably. This
patient’s serum concentrations and AUC for phenytoin
decreased by 50% at a GBP dose of 4800 mg per day,
however, the patient’s serum levels had fluctuated at
lower GBP doses, raising concerns about compliance.
The other two patients on phenytoin did not demon-
strate a similar fluctuation.
These findings support the claim that GBP does
not cause a PK interaction with other anti-epileptic
drugs, therefore, it is unlikely to cause toxicity from
concomitant administration, however, a pharmacody-
namic interaction may occur.
CONCLUSIONS
This is the first reported study to evaluate detailed
inter-dose serum concentration profiles and determine
PKs of GBP at five separate dosage levels, in the same
patients under routine clinical treatment conditions.
In four of six patients the bioavailability of GBP was
maintained when the dose exceeded the maximum
recommended. Furthermore, despite its rapid serum
elimination half-life, it is concluded that it may be
possible to dose GBP only twice daily since plasma
concentrations do not fluctuate greatly between dose
intervals.
The present work proves GBP is transported into
saliva and that during maintenance dose salivary GBP
concentrations are 5–10% of those in serum although
they fluctuate markedly both within and between indi-
viduals. Our findings also indicate that there is a linear
relationship between GBP salivary levels and dosage
increments up to 4800 mg per day. However, the low
and fluctuating levels GBP in saliva will only pro-
vide a means of confirming that the patient has taken
GBP rather than meeting the more demanding rigor of
therapeutic monitoring in clinical practice.
Finally, it is concluded that larger than recom-
mended GBP doses do not affect either the steady state
serum concentrations or between dose interval AUC’s
of a range of commonly prescribed anti-epileptic
medications or their metabolites.
Therapeutic monitoring of GBP maybe somewhat
controversial, but several reports18–22 suggest it may
be beneficial during individualisation of GBP treat-
ment and it would certainly help to identify those pa-
tients who are able to absorb more than the currently
commended maximum dose and the potential clini-
cal benefit which might accrue from this. In addition
it will identify unexpected accumulation of GBP in
cases where a disturbance of renal function has been
previously unsuspected.
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